All In Biotech

Drug Trial Radar · NCT07901244

An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease

A Phase 2b/3, Open-label, Multicenter, Study to Evaluate the Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

356

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Dec 2028

Study completion Jan 2029

Sponsor

Lead sponsor
Biohaven Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To study the long-term safety and tolerability of BHV-1300

Conditions

  • Graves' Disease

Interventions

  • BHV-1300Drug

    delivered subcutaneously via autoinjector

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of SAEs, severe AEs, AEs leading to discontinuation, or deathsTime frame: Baseline to Week 52
  2. Frequency of clinically significant laboratory abnormalitiesTime frame: Baseline to Week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.